Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of PBCLN-003 in C. Difficile-associated Diarrhea
NCT03793686Phase 1Terminated
- Sponsor
- Prolacta Bioscience
- Start
- Dec 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Clostridium difficile infection (CDI) comparing PBCLN-003 with Placebo (2 arms). Primary endpoint: Characterization of Adverse Events up to 8 Weeks. Started Dec 2018; status: terminated.
02
Drugs
PBCLN-003
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT03793686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793686.